Boji Medical Technology Co.Ltd(300404) ( Boji Medical Technology Co.Ltd(300404) ) on March 4, the company issued a document on its official wechat that the signing ceremony of phase III clinical trial cooperation between the company and Yicheng biological’s “epiutide nasal drops” in the treatment of allergic rhinitis was held online in Guangzhou and Wuhan at the same time. The signing ceremony marks that the class 1 new drug “epiutide nasal drops” is about to enter the key phase III clinical research stage of applying for a new drug certificate.
“Yipiutide nasal drops” is a new class 1 chemical medicine. It is the first preparation developed for a variety of nasal inflammation with yipiutide as the API. It is developed by Wuhan Yicheng Biotechnology Co., Ltd. Boji Medical Technology Co.Ltd(300404) will provide phase III clinical research and subsequent drug registration services for the project.
Epiutide is a specific inhibitor of p55PIK, a member of PI3K subtype, developed by Wuhan Yicheng Biotechnology Co., Ltd. It can treat inflammatory diseases through a variety of effector mechanisms: inhibiting inflammation and participating in cell proliferation; Inhibit NF, which plays an important role in the inflammatory process- κ B activates the signal transduction mechanism and inhibits the production and secretion of inflammatory mediators; Regulate the inflammatory process and slow down the aggregation and invasion of inflammatory cells; Inhibit angiogenesis at the inflamed site.
The company said that at present, the research and development of iputide in the treatment of allergic rhinitis has completed the phase II clinical trial and plans to carry out the phase III clinical trial. The results of phase I clinical trial showed that it was well tolerated and safe, and the results of phase II clinical trial showed that iputide was better than placebo in many efficacy indexes. The listing of epiutide will give patients with allergic rhinitis more choices. At the same time, because there is no anti-inflammatory drug with the same action mechanism as iputide outside China, iputide has a broad market prospect.
